Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty

IntroductionOvarian cancer (OVCA) has a five-year survival rate of approximately 45%, with little improvement over recent decades. Although anti-PD-L1 therapies have shown substantial efficacy in other solid tumors, their effectiveness in OVCA has been limited. These treatments target only membranou...

Full description

Saved in:
Bibliographic Details
Main Authors: Meshach Asare-Werehene, Arvin Zaker, Shivanshi Tripathi, Laudine Communal, Euridice Carmona, Anne-Marie Mes-Masson, Benjamin K. Tsang, Arvind Mer
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Immunology
Subjects:
PD-L1
immunotherapy
nuclear PD-L1
ovarian cancer
chemoresistance
tumor microenvironment
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543529/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2025.1543529/full

Similar Items